The Correlation Between Sleep and Coronary Heart Disease: A Review

Abstract

Coronary heart disease (CHD), which is characterized by the coronary arteries narrowing or becoming obstructed due to atherosclerosis, leads to myocardial ischemia, hypoxia, or necrosis. Owing to an aging population and lifestyle changes, the incidence of CHD and subsequent mortality rates continue to rise, making CHD one of the leading causes of disability and death worldwide. Hypertension, diabetes, hyperlipidemia, smoking, obesity, and genetic factors are considered major risk factors for CHD; however, these factors do not fully explain the complexity and diversity in the etiology of CHD. Sleep, an indispensable part of human physiological processes, is crucial for maintaining physical and mental health. In recent years, the rapid pace of modern life has led to an increasing number of patients experiencing an insufficient amount of sleep, declining sleep quality, and sleep disorders. Therefore, the correlation between sleep and CHD has become a focal point in current research. This review aims to address the relationship between sleep duration, quality, and sleep disorder-related diseases with CHD and emphasizes potential underlying mechanisms and possible clinical implications. Moreover, this review aimed to provide a theoretical basis and clinical guidance for the prevention and treatment of CHD.

Graphical abstract

Keywords

coronary heart disease / sleep duration / sleep quality / sleep disorders

1. Introduction

Ischemic heart disease, also called coronary heart disease (CHD), is caused by the narrowing or obstructions of coronary arteries as a result of the buildup of atherosclerosis, which can lead to myocardial ischemia and hypoxia, and ultimately myocardial necrosis. Aging and lifestyle changes have led to an increase in CHD which has resulted in increased mortality, and is now a major global health threat [1]. Although significant progress has been made in the diagnosis and treatment of CHD over the past few decades, the global economic burden of ischemic heart disease continues to increase [2]. The etiology and pathogenesis of CHD have long been a focus of research. The development of CHD is a complex process affected by multiple risk factors including aging, smoking, obesity, hypertension, diabetes, dyslipidemia, and genetic predisposition. These risk factors promote the formation and progression of coronary atherosclerosis through mechanisms such as lipid infiltration, endothelial injury, smooth muscle cell proliferation and migration, platelet aggregation, and thrombosis [3]. However, the exact causes and mechanisms of CHD remain unclear and require further investigation. A comprehensive understanding of the etiology and pathogenesis of CHD is crucial for developing more effective preventive measures, accurate diagnostic methods, and treatment strategies.

Sleep is a basic physiological process that is essential to overall health and cardiovascular function [4]. Good sleep not only helps to restore physical strength, promote tissue repair, and cell regeneration, but also enhances immune function, regulates metabolic processes, and maintains the balance of the endocrine system [5, 6]. However, with the fast-paced lifestyle, an increasing number of people are suffering from insufficient sleep, declining sleep quality, and sleep disorders. In China, approximately one-quarter of adolescents experience sleep disorders [7]. Furthermore, with increasing age, the incidence of sleep disorders tends to rise, with more than one-third of elderly individuals reporting sleep disturbances [8]. Research has shown that insufficient sleep, excessive sleep duration, poor sleep quality, and sleep disorder-related diseases all increase the risk of cardiovascular diseases (CVD), including CHD, angina, and myocardial infarction. In contrast, a healthy sleep pattern (such as early bedtime, 7–8 hours of sleep per night, rarely or never suffering from insomnia, no sleep apnea, and not frequently experiencing excessive daytime sleepiness) can significantly reduce the incidence of CHD, CVD, and stroke [9, 10]. In 2022, the American Heart Association updated its “8 Factors for Cardiovascular Health” assessment system, and for the first time, incorporating sleep health in the guidelines [11]. Therefore, there exists a close and complex relationship between sleep and CHD, as well as major adverse cardiovascular events (MACE), which holds significant value for the prevention and treatment of CHD.

This review addresses the relationship between sleep duration, quality, and sleep disorder-related diseases with CHD and emphasizes potential underlying mechanisms and possible clinical implications. The aim is to offer a theoretical foundation and clinical guidance for the prevention and treatment of CHD. The graphical abstract is shown in Fig. 1.

2. The Correlation Between Sleep Duration and CHD

The American Heart Association guidelines indicate that the optimal sleep duration for adults is between 7 to 9 hours per night [11]. Another study suggests that the best time to sleep is between 10 and 11 PM [12]. However, with changes in lifestyle, the average sleep duration has gradually decreased, and insufficient sleep has become an increasingly common phenomenon [13]. A survey involving 444,306 participants showed that over one-third of the subjects slept less than 7 hours per night, 23.0% of them slept 6 hours per night, and 11.8% slept less than 5 hours each night [14]. The reduction in sleep duration is closely linked to changes in lifestyle, such as intense work and study schedules, the use of electronic devices before bed, and more active nighttime social activities. Furthermore, sleep disorders related diseases, such as insomnia and obstructive sleep apnea (OSA), are significant contributors to sleep deprivation [15]. The relationship between insufficient sleep and CHD has been a focal point of research, with growing evidence suggesting that inadequate sleep is closely linked to the onset and progression of CHD. However, the relationship between prolonged sleep duration and CHD remains controversial. While some studies suggest that prolonged sleep duration may elevate the risk of CHD, others have reported no significant association between extended sleep and the risk of CHD [16, 17].

Several studies have demonstrated a strong relationship between decreased periods of sleep and the risk for CHD. Ayas et al. [18] conducted a decade-long follow-up of 71,617 initially healthy women to examine the association between self-reported sleep duration and the incidence of CHD. After accounting for multiple potential confounders, such as snoring, body mass index, and smoking, the adjusted relative risks for CHD (95% confidence interval [CI]) were 1.45 (1.10–1.92) for those sleeping five hours or less, 1.18 (0.98–1.42) for six hours, and 1.09 (0.91–1.30) for seven hours. The Whitehall II study followed 10,308 healthy adults for 15 years and found that the relative risk of CHD was highest among those with insufficient sleep accompanied by sleep disorders (relative risk [RR]: 1.55, 95% CI: 1.33–1.81) [19]. Research has also shown that individuals with very short sleep durations (\le5 hours) are also closely associated with the occurrence of unstable angina odds ratio [OR]: 3.241, 95% CI: 1.772–5.925) and myocardial infarction (OR: 2.525, 95% CI: 1.113–5.728) [20]. Barger et al. [21] conducted a 2.5-year follow-up study on 13,026 patients with acute coronary syndrome (ACS) (within 30 days of onset). Patients who reported 6 hours of sleep per night had a 29% higher risk of major coronary events (MCE; CHD death, myocardial infarction, or urgent revascularization) (adjusted hazard ratio [HR]: 1.29; 95% CI: 1.12–1.49; p 0.001) compared with those with longer periods of sleep. Additionally, for individuals who slept less than 6 hours on weekdays, sleeping an additional 2 hours on weekends was associated with a significant reduction in the incidence of angina, CHD, and other CVD [22]. These studies consistently suggest that insufficient sleep increases the risk of CHD and MACE, making insufficient sleep a potential risk factor for CHD.

Several prospective cohort studies have shown that both short and long periods of sleep are associated with an increased risk of CHD. Wang et al. [23] conducted an 18-year follow-up study of 12,268 twin individuals without CVD at baseline (mean age = 70.3 years) to examine the incidence of CVD. In a fully adjusted Cox model, compared to those sleeping 7 to 9 hours per night, the hazard ratios (HRs) for CVD were 1.14 (95% CI: 1.01–1.28) for individuals sleeping fewer than 7 hours and 1.10 (95% CI: 1.00–1.21) for those sleeping 10 or more hours per night. Another large prospective cohort study [24] included 392,164 adults and analyzed the relationship between sleep duration and CHD mortality. The results revealed that, compared to the normal sleep duration of 6 to 8 hours per night, individuals who slept less than 4 hours and more than 8 hours had a 34% (HR: 1.34, 95% CI: 0.87–2.07) and 35% (HR: 1.35, 95% CI: 1.11–1.65) increased risk of death from CHD, respectively. Furthermore, subgroup analyses by gender and age showed that this U-shaped relationship was more pronounced in women and the elderly. Other studies have also indicated that individuals sleeping 7 hours per night have the lowest all-cause, CVD, and other causes of mortality rates [25]. Meta-analyses also indicate a U-shaped relationship between sleep duration and CHD [26, 27, 28]. Yin et al. [27] identified a U-shaped relationship between sleep duration and the risks of all-cause mortality, total cardiovascular disease, CHD, and stroke, with the lowest risk observed at around seven hours of sleep per day. Each one-hour decrease in sleep duration was associated with a pooled RR for CHD of 1.07 (95% CI: 1.03–1.12), while each one-hour increase corresponded to a pooled RR of 1.05 (95% CI: 1.00–1.10). Therefore, both short and long sleep durations are associated with CHD and MACE, but the optimal sleep duration remains a subject of ongoing debate.

Although a U-shaped relationship has been widely reported, several studies dispute the relationship of long sleep duration to CHD risk and point to areas for future study. For example, a study involving 20,432 participants aged 20–65 years without a history of CVD found no significant correlation between long sleep duration (\ge9 hours) and the incidence of CHD or CVD during a 10–15 year follow-up period [16]. Genetic variants associated with continuous, short (\le6 h) and long (\ge9 h) sleep durations were used to examine the causal associations with 12 CVDs among 404,044 UK Biobank participants of White British ancestry. Additional analyses reinforced the detrimental impact of genetically predicted short sleep duration on the risk of 5 out of 12 CVDs, specifically arterial hypertension, pulmonary embolism, coronary artery disease, myocardial infarction, and chronic ischemic heart disease (p 0.001), while also indicating a potential association with atrial fibrillation (p 0.05). In contrast, no significant relationship was observed between genetically predicted long sleep duration and any form of CVD [17]. These findings challenge the view that prolonged sleep duration increases the risk of CHD and CVD, suggesting that the relationship between long sleep duration and CHD, as well as other CVDs, requires further investigation and confirmation.

3. The Correlation Between Sleep Quality and CHD

Sleep quality includes subjective and objective measures such as sleep duration, efficiency, continuity, and depth. In 1989, Buysse et al. [29] developed the Pittsburgh Sleep Quality Index (PSQI), which assesses sleep quality across seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. The PSQI reflects an individual’s sleep quality over the past month and is currently one of the most commonly used tools for evaluating sleep quality. In 2022, Nelson et al. [30] also conducted a conceptual analysis of sleep quality and identified four key attributes: sleep efficiency, sleep latency, sleep duration, and awakenings after sleep onset. Good sleep quality is essential for an individual’s physical and mental health, quality of life, and overall well-being. However, sleep quality has been declining in modern society. Various factors, including physical conditions (such as bodily illnesses), psychological factors (such as stress, anxiety, and depression), environmental factors (such as noise, light, and temperature), and the use of certain medications, can all negatively impact sleep quality. Research has clearly indicated a significant association between sleep quality and both CVD and CHD [16, 31, 32].

Twig et al. [32] conducted a follow-up study involving 26,023 males (mean age: 30.9 \pm 5.6 years) over an average period of 6.4 \pm 4.1 years to evaluate the association between baseline sleep quality and the incidence of diabetes and CHD. The results revealed that poor sleep quality plays a role in the onset of both conditions, with its impact increasing over time. Zhang et al. [33] also conducted a survey on 27,935 participants (11,177 males and 16,758 women) from rural areas in Henan Province to explore the independent and interactive relationships between nighttime sleep duration, sleep quality, and CHD. The results indicated that both poor sleep quality and insufficient sleep duration were associated with an increased prevalence of CHD. Additionally, individuals with both insufficient sleep duration and poor sleep quality had the highest proportion of CHD. Another study followed 9570 participants without CHD for 8 years, during which 411 participants (4.29%) developed CHD [34]. After adjusting for conventional CHD risk factors and sleep duration, the relative risks of CHD were significantly higher in the moderate sleep quality group (HR: 1.393; 95% CI: 1.005–1.931) and the poor sleep quality group (HR: 1.913; 95% CI: 1.206–3.035) compared to the good sleep quality group. Poor sleep quality may represent a novel and modifiable risk factor for CHD, independent of traditional cardiovascular risk factors, even when sleep duration remains within the normal range.

Poor sleep quality is a risk factor for disease progression and MACE in patients with coronary heart disease. Andrechuk et al. [35] assessed the relationship between sleep quality during hospitalization and the occurrence of MACE including cardiovascular death, recurrent cardiovascular ischemic events, and stroke in patients with acute myocardial infarction (AMI). The results showed that 12.4% of patients experienced MACE, and this was independently associated with poor sleep quality. Yang et al. [36] studied the relationship between sleep quality and the severity of coronary artery lesions as well as prognosis in young patients with ACS. The findings indicated that persistent poor sleep quality is a contributing factor to the development of complex coronary artery lesions. Moreover, prolonged poor sleep quality (PSQI >5) was strongly linked to a higher risk of MACE, with a HR of 4.266 (95% CI: 2.274–8.001). In diabetic populations, a healthy sleep pattern is significantly associated with a reduced risk of CHD and CVD mortality [37]. Some researchers argue that sleep quality has a more significant impact on CHD than sleep duration [38, 39]. Therefore, improving sleep quality is not only an effective way to enhance individual health but also one of the key strategies for preventing CHD. Future research should further explore the long-term benefits of improved sleep quality on cardiovascular health and develop new interventions to enhance public sleep quality.

4. The Common Sleep Disorders and Their Association With CHD

Sleep disorders are common in adults and are frequently linked to adverse outcomes, such as diminished quality of life and heightened risk for mortality. Among the most prevalent types are insomnia, OSA, and restless legs syndrome (RLS) [40]. The connection between sleep disorders and CHD has been a longstanding focus of research in the medical and public health domains.

4.1 The Correlation Between Insomnia and CHD

Insomnia is the most common type of sleep disorder. The American Academy of Sleep Medicine defines insomnia as a condition characterized by sufficient opportunities for sleep but with significant issues in the initiation, consolidation, duration, or quality of sleep, accompanied by daytime functional impairments [41]. The diagnosis of chronic insomnia can be made when these symptoms occur at least three times per week and persist for more than three months. Daytime functional impairments include fatigue or general discomfort, difficulties with concentration or memory, irritability or emotional instability, daytime sleepiness, or any other form of impaired social or occupational functioning. Studies have found that the prevalence of insomnia ranges from 15% to 24%, with an increasing trend over time [42, 43, 44]. Short-term insomnia may lead to various emotional problems, such as excessive daytime sleepiness, mood swings, irritability, and heightened concerns about sleep quality. Chronic insomnia, on the other hand, can result in severe physical health issues, including cognitive dysfunction, endocrine disturbances, and CVD [45]. Insomnia, as a common sleep disorder, has been widely confirmed to be closely associated with an increased risk of developing CHD.

Multiple studies have shown that insomnia not only increases the prevalence of CHD but is also closely associated with ACS and MACE [46, 47, 48, 49, 50]. More than one-third of patients with ACS report moderate to severe insomnia symptoms during their hospitalization [48]. Laugsand et al. [49] conducted a follow-up study of 52,610 healthy participants over a period of 11.4 years to assess the impact of insomnia symptoms on the risk of AMI. After adjusting for confounding factors, the risk of AMI was found to increase by 27% to 45% due to various insomnia symptoms. The symptom most strongly associated with myocardial infarction was difficulty falling asleep. Furthermore, when multiple insomnia symptoms were considered together, the relationship between insomnia and myocardial infarction exhibited a dose-dependent pattern. Frøjd et al. [51] also conducted a follow-up study of 1068 patients who had experienced a myocardial infarction or undergone coronary artery revascularization, with an average follow-up period of 4.2 years. The results showed that, compared to patients without insomnia, those with insomnia had a 62% increased relative risk of experiencing MACE after adjusting for age and sex (RR: 1.62; 95% CI: 1.24–2.11). Even after adjusting for risk factors, cardiovascular comorbidities, and symptoms of anxiety and depression, the association between insomnia and MACE remained significant (RR: 1.41; 95% CI: 1.05–1.89).

Several meta-analyses have further confirmed the association between insomnia and an increased risk of CHD and MACE. The results of these meta-analyses indicate that insomnia is significantly associated with an increased incidence of myocardial infarction (RR: 1.69, 95% CI: 1.41–2.0). Sleep disturbances related to sleep initiation and maintenance are also associated with a higher incidence of myocardial infarction (RR: 1.13; 95% CI: 1.04–1.23) [52]. Another meta-analysis, which included 13 prospective studies and followed 122,501 participants without CVD for 3 to 20 years, found that insomnia was associated with a 45% increased risk of CVD or death (RR: 1.45; 95% CI: 1.29–1.62) [53]. Another meta-analysis, which included 17 cohort studies involving 311,260 individuals without baseline CVD, found that the relative risk of CVD-related mortality was 33% higher in individuals with insomnia (95% CI: 1.13–1.57) [54]. These findings highlight the potential harm of insomnia to cardiovascular health and underscore the importance of recognizing and managing insomnia in clinical practice to mitigate its contribution to the risk of CVD.

4.2 The Correlation Between OSA and CHD

OSA also known as obstructive sleep hypopnea syndrome, is another common sleep disorder-related condition. It is characterized by recurrent partial and complete upper airway obstruction, leading to intermittent hypoxemia, autonomic nervous system dysfunction, and sleep fragmentation [55, 56]. The symptoms of OSA include frequent apneas, snoring, nocturnal awakenings, morning headaches, daytime sleepiness, and difficulty concentrating, all of which severely affect the patient’s sleep quality and daily life. Studies suggest that approximately half of the global population is affected by OSA [57]. As the population of overweight and obese individuals continues to grow, the prevalence of OSA is also steadily increasing. The prevalence of OSA is even higher among patients with CHD, stroke, heart failure, and arrhythmias, reaching 65%, 75%, 55%, and 50%, respectively [58]. Unfortunately, the diagnosis of OSA remains suboptimal. Among individuals with clinically significant OSA identified in population studies, as many as 86% to 95% of patients have not been diagnosed with the condition [59]. In cardiovascular medical practice, the recognition and treatment of OSA remain insufficient.

Study has shown that moderate to severe OSA is associated with increased volume of total atherosclerosis in patients with CHD [60]. The association remained significant even after adjusting for cardiovascular risk factors such as BMI, diabetes and high blood pressure. Mooe et al. [61] found that the severity of hypoxemia during sleep is a major determinant of ST-segment depression on the electrocardiogram, and that OSA patients are more likely to experience AMI during the night. Hao et al. [62] recruited 1927 patients with ACS and conducted a follow-up for an average of 2.9 years to assess the impact of OSA on the prognosis of ACS patients. The results showed that OSA was independently associated with the occurrence of MACE in ACS patients. In those with a history of myocardial infarction, OSA increased the risk of MACE by 1.74 times (adjusted HR: 1.74; 95% CI: 1.04–2.90). OSA is also associated with an increased risk of MACE in CHD patients following percutaneous coronary intervention. In patients with ST-segment elevation myocardial infarction who also have OSA, the survival rate without cardiovascular events over the subsequent 18 months is significantly lower [63]. Studies have also shown that OSA is more likely to lead to coronary artery calcification [64], plaque instability [65], and vulnerable plaques [66]. Data from the previous meta-analysis showed that there is also a strong association between OSA and cardiometabolic markers such as triglyceride-glucose index (TyG), lipid accumulation product (LAP) and lipid accumulation product (AIP) [67, 68]. Therefore, long-term OSA can affect the vasculature, heart, and brain, contributing to the development of CHD, heart failure, stroke, diabetes, and even an increased risk of mortality. The inclusion of sleep assessment in cardiovascular risk stratification is helpful for the early identification and intervention of patients with CHD and the prevention of adverse cardiovascular events [69].

Continuous positive airway pressure (CPAP) is the primary treatment for OSA and can significantly improve patients’ sleep quality, daytime sleepiness, and overall quality of life. Studies have confirmed that CPAP not only improves sleep symptoms in moderate to severe OSA patients but can also lower blood pressure. Additionally, it can reduce troponin and brain natriuretic peptide (BNP) levels, offering some improvement in myocardial injury [70]. A study published in The Lancet followed OSA patients for 10.1 years and found that, among male patients, severe OSA significantly increased the risk of both fatal and non-fatal cardiovascular events, but that CPAP treatment was shown to reduce this risk [71]. However, one study showed that in CHD patients with non-somnolent OSA, routine CPAP treatment does not significantly improve long-term cardiovascular outcomes [72]. Meta-analyses suggest that CPAP use in CHD patients with OSA may help prevent subsequent cardiovascular events. However, this finding has only been confirmed in observational studies and has not been validated in randomized controlled trials [73]. Therefore, there is still some controversy regarding whether CPAP treatment can reduce the occurrence of MACE [74]. However, for CHD patients, screening for OSA and providing appropriate treatment are necessary [58].

4.3 The Correlation Between RLS and CHD

RLS is a common neuro-sensory-motor disorder characterized by an uncontrollable urge to move the legs and uncomfortable sensations in the legs, primarily occurring at night and during periods of rest. It significantly impacts sleep and quality of life and is one of the common sleep disorder-related conditions [75]. A meta-analysis on the epidemiology of RLS estimated that the prevalence of RLS in the general population ranges from 5% to 8%. Most patients experience mild RLS symptoms, and the prevalence of RLS gradually increases with age [76]. Studies have shown that RLS often coexists with conditions that are associated with an increased risk of CHD, such as obesity, hypercholesterolemia, and diabetes [77, 78]. It has also been shown that the prevalence of RLS is related to coronary artery disease and coronary artery disease severity [79]. It is speculated that RLS may be related to vascular endothelial dysfunction in CHD. Almuwaqqat et al. [80] conducted a 5-year follow-up study of 3266 CHD patients undergoing coronary angiography. After adjusting for demographic and clinical risk factors, the results revealed that moderate to severe RLS patients had a significantly higher risk of major adverse events (cardiovascular death or myocardial infarction) compared to those without RLS (HR: 1.33; 95% CI: 1.01–1.76). This association was particularly more pronounced in males. Therefore, moderate to severe RLS may be an independent risk factor for cardiovascular adverse outcomes. However, one study showed that primary RLS is not associated with the onset of CVD or coronary artery disease [81]. Therefore, the relationship between RLS and CHD requires further investigation.

5. Potential Mechanisms of Poor Sleep Leading to CHD

The impact of poor sleep on heart health is widely recognized in the scientific community; however, the specific mechanisms by which poor sleep leads to CHD remain unclear. A summary of previous studies suggests that poor sleep may promote the development of atherosclerosis and CHD through mechanisms such as inflammation, oxidative stress, autonomic nervous system dysfunction, metabolic and endocrine disturbances, and coagulation abnormalities.

5.1 Inflammation

Inflammation has long been considered a key factor in the development of atherosclerosis [82, 83]. Inflammatory mediators, such as tumor necrosis factor-alpha (TNF-\alpha), interleukin-1\beta (IL-1\beta), interleukin-6 (IL-6), interleukin-17 (IL-17), and C-reactive protein (CRP), play important roles in chronic inflammatory responses. These mediators can promote lipid accumulation, thereby driving the development and progression of atherosclerosis and CHD [84]. The specific mechanisms by which poor sleep leads to CHD and MACE remain unclear, but inflammation may be one of the underlying mechanisms [85]. An animal study has shown that prolonged sleep deprivation for four consecutive days can lead to neutrophil aggregation and an inflammatory storm in mice, resulting in multi-organ dysfunction [86]. In healthy adults, compared to adequate sleep, even a single night of partial sleep deprivation (with sleep limited to 4 hours) leads to a significant increase in the levels of IL-6 and TNF-\alpha produced by monocytes the following day [87]. Partial sleep deprivation not only promotes the activation of lymphocytes and the production of inflammatory mediators such as IL-1\beta, IL-6, and IL-17, but even after two nights of restorative sleep, these inflammatory mediators remain elevated, accompanied by increased heart rate and serum CRP levels [88]. Parthasarathy et al. [89] also found in a prospective study that participants with chronic persistent insomnia had a significantly higher cardiovascular and respiratory mortality rate, which was closely associated with a marked increase in the level of inflammation. In addition, the levels of inflammatory mediators are significantly elevated in OSA patients, and these inflammatory markers increase the risk of atherosclerosis and the development of CHD [90, 91, 92]. Wen et al. [93] also showed that, compared to the OSA-only group, patients with both OSA and CHD had significantly elevated levels of CRP, TNF-\alpha, IL-6, and interferon-\gamma. Long-term periods of poor sleep may lead to persistent changes in the immune system and a chronic inflammatory state, increasing the risk of developing CHD and MACE. Therefore, sleep-targeted interventions may become a new strategy for suppressing inflammation and could have a significant impact on reducing the risk of inflammation-related diseases.

5.2 Oxidative Stress

The dynamic balance between reactive oxygen species (ROS) and antioxidants plays a crucial role in maintaining normal cellular function. Oxidative stress induced by excessive ROS has become one of the primary mechanisms driving the development of atherosclerosis [94]. Oxidative stress can promote the formation and progression of atherosclerosis through mechanisms such as inflammation, endothelial dysfunction, and the proliferation and migration of endothelial cells and smooth muscle cells [95]. Poor sleep is closely associated with oxidative stress, and therefore, oxidative stress may be another important mechanism by which poor sleep contributes to the development of CHD [96]. Vaccaro et al. [97] used experiments in fruit flies and mice to demonstrate that sleep deprivation leads to the accumulation of ROS and increases oxidative stress levels in the body. The mortality caused by severe sleep restriction may be due to oxidative stress. A randomized crossover design study [98] also showed that six weeks of sleep restriction impaired the ability of endothelial cells to clear ROS, increased oxidative stress levels in endothelial cells, and led to endothelial dysfunction. This may, over time, increase the risk of developing CVD. Short-term sleep restriction has also been associated with elevated levels of myeloperoxidase, an enzyme involved in the formation of oxidants. Myeloperoxidase can modify low-density lipoprotein cholesterol into oxidized low-density lipoprotein cholesterol, exacerbating endothelial damage and lipid accumulation, thus promoting the progression of atherosclerosis [99, 100]. Nighttime intermittent hypoxia in OSA patients is closely associated with increased oxidative stress, elevated inflammatory cytokines, imbalance in nitric oxide production, and endothelial injury. CPAP has been shown to significantly improve oxidative stress, inflammation, and endothelial dysfunction caused by OSA [101]. Therefore, poor sleep may promote the development of atherosclerosis and CHD through oxidative stress. Good sleep not only alleviates oxidative stress but may also have a protective effect on cardiovascular health.

5.3 Autonomic Nervous System Dysfunction

The autonomic nervous system plays a crucial role in maintaining cardiovascular homeostasis by regulating heart rate, blood pressure, vascular tone, and cardiac contractility to ensure normal cardiovascular function. Dysregulation of the autonomic nervous system, particularly excessive activation of the sympathetic nervous system, is closely associated with various CVDs such as CHD, arrhythmias, and hypertension [102, 103]. Since it may be a potential mechanism by which sleep problems contribute to CHD and CVD, autonomic nervous system function has been widely studied [104]. Most research data indicate that insufficient sleep leads to excessive activation of the sympathetic nervous system [105, 106]. Compared to patients with adequate sleep, those with insufficient sleep or insomnia show significantly higher concentrations of norepinephrine in both their blood and urine [107, 108]. Sympathetic nervous system overactivation caused by poor sleep leads to an increased heart rate and reduced heart rate variability [109]. An increased heart rate shortens ventricular diastolic time and myocardial blood flow perfusion time, increasing the risk of atherosclerosis, thrombosis, and myocardial ischemia. An epidemiological study has reported that hypertension, a common risk factor for CHD, is closely linked to sympathetic nervous system overactivation caused by insufficient sleep [110, 111]. Blood pressure fluctuations, hypoxemia, and hypercapnia caused by OSA can also activate the sympathetic nervous system through pressure receptors, as well as central and peripheral chemoreceptors [112, 113, 114]. Sympathetic activity increased significantly with increasing severity of OSA [115]. Autonomic dysfunction caused by insufficient sleep may also lead to endothelial dysfunction [116, 117], inflammation [118], and an increased risk of CHD and CVD. Therefore, interventions targeting autonomic dysfunction caused by sleep disturbances may become an effective strategy to reduce the risk of CHD and improve patient outcomes.

5.4 Metabolic and Endocrine Disorders

The metabolic syndrome is a pathological condition characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. Each component of metabolic syndrome contributes to an increased risk of CHD [119]. Studies have shown a close association between insufficient sleep and obesity, which may be related to increased hunger and appetite in sleep-deprived individuals, along with a reduction in daily physical activity and energy expenditure [120, 121, 122]. Insomnia patients with shorter sleep duration have a significantly higher risk of developing diabetes [123]. Insomnia can also lead to an increase of nearly 23% in fasting blood glucose levels and a nearly 48% increase in fasting insulin levels in diabetic patients [124]. This suggests that insomnia not only increases the risk of developing diabetes, but is also closely associated with poor blood glucose control and insulin resistance in diabetic patients. Wang et al. [125] also suggested that sleep patterns (such as sleep duration, sleep type, insomnia, snoring, and daytime sleepiness) interact with glucose tolerance in relation to CVD. Poor sleep patterns may increase the risk of diabetes, thereby contributing to a higher prevalence of CVD. Liang et al. [126], using genetic data, predicted a moderate association between short sleep duration and metabolic syndrome, as well as several of its core components, including central obesity, dyslipidemia, hypertriglyceridemia, and hyperglycemia. However, long sleep duration was not found to be associated with metabolic syndrome or any of its components. Liu et al. [127] also showed that genetically predicted insomnia is consistently associated with higher body mass index, triglycerides, and lower high-density lipoprotein cholesterol levels, with each of these factors potentially playing a mediating role in the causal pathway between insomnia and various cardiovascular disease outcomes. There is also evidence suggesting that insomnia patients, especially those with objectively short sleep duration, exhibit significantly increased hypothalamic-pituitary-adrenal (HPA) axis activity, accompanied by elevated secretion of stress hormones such as adrenal corticosteroids and cortisol [128, 129, 130, 131]. Chronic activation of the HPA axis and endocrine dysfunction also increase the risk of developing metabolic syndrome and CHD.

5.5 Abnormal Coagulation Function

Under normal physiological conditions, the body’s coagulation and fibrinolytic systems maintain a dynamic balance to prevent excessive bleeding and thrombus formation. Coagulation dysfunction, including increased activity of coagulation factors, enhanced platelet function, or impaired fibrinolytic system activity, are key factors in the development of CHD and MACE [132, 133]. Platelets play a crucial role in atherosclerosis and acute thrombotic events [134, 135]. One night of sleep deprivation can promote the release of extracellular vesicles into the bloodstream, inducing platelet activation and increasing the risk of thrombosis [136]. Other studies [137, 138] suggest that OSA not only promotes platelet activation but also impairs fibrinolytic system function, leading to a hypercoagulable state. This may be related to intermittent hypoxia, increased sympathetic nervous activity, systemic inflammation, and endothelial dysfunction induced by OSA. A hypercoagulable state and impaired fibrinolytic system function can lead to thrombotic events, which is one of the potential mechanisms linking OSA to adverse cardiovascular and cerebrovascular events. In healthy individuals, sleep disruption significantly increases the levels of soluble tissue factor and von Willebrand factor in the blood, suggesting that sleep disruption is associated with elevated biomarkers of thrombotic risk in the cardiovascular system [139]. Additionally, plasma levels of von Willebrand factor are significantly higher in individuals with a nightly sleep duration of either less than 7 hours or more than 7 hours compared to those with a sleep duration of 7 hours per night [140]. Therefore, coagulation dysfunction is one of the important mechanisms through which poor sleep contributes to the development of CHD and MACE.

6. Conclusion

Sleep duration, sleep quality, and sleep-related disorders are intricately linked to the development of CHD and the incidence of MACE. Poor sleep may contribute to the development of CHD and MACE through several pathways, including inflammation, oxidative stress, autonomic dysfunction, metabolic and endocrine disorders, and coagulation abnormalities. Therefore, incorporating sleep assessment into cardiovascular risk stratification and early identification and intervention strategies are essential for the prevention of CHD and MACE. However, the precise mechanisms through which poor sleep leads to CHD remain unclear, and maintaining healthy sleep patterns continues to be a challenge. Further research is necessary to define these mechanisms and to develop better strategies to promote improved sleep duration and quality into clinical practice to decrease the incidence of CHD and MACE.

References

[1] Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020; 76: 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.

[2] Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023; 44: 3720–3826. https://doi.org/10.1093/eurheartj/ehad191.

[3] Ajoolabady A, Pratico D, Lin L, Mantzoros CS, Bahijri S, Tuomilehto J, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death & Disease. 2024; 15: 817. https://doi.org/10.1038/s41419-024-07166-8.

[4] Maniaci A, Lavalle S, Parisi FM, Barbanti M, Cocuzza S, Iannella G, et al. Impact of Obstructive Sleep Apnea and Sympathetic Nervous System on Cardiac Health: A Comprehensive Review. Journal of Cardiovascular Development and Disease. 2024; 11: 204. https://doi.org/10.3390/jcdd11070204.

[5] Besedovsky L, Lange T, Haack M. The Sleep-Immune Crosstalk in Health and Disease. Physiological Reviews. 2019; 99: 1325–1380. https://doi.org/10.1152/physrev.00010.2018.

[6] Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet (London, England). 1999; 354: 1435–1439. https://doi.org/10.1016/S0140-6736(99)01376-8.

[7] Liang M, Guo L, Huo J, Zhou G. Prevalence of sleep disturbances in Chinese adolescents: A systematic review and meta-analysis. PloS One. 2021; 16: e0247333. https://doi.org/10.1371/journal.pone.0247333.

[8] Lu L, Wang SB, Rao W, Zhang Q, Ungvari GS, Ng CH, et al. The Prevalence of Sleep Disturbances and Sleep Quality in Older Chinese Adults: A Comprehensive Meta-Analysis. Behavioral Sleep Medicine. 2019; 17: 683–697. https://doi.org/10.1080/15402002.2018.1469492.

[9] Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. European Heart Journal. 2020; 41: 1182–1189. https://doi.org/10.1093/eurheartj/ehz849.

[10] Nambiema A, Lisan Q, Vaucher J, Perier MC, Boutouyrie P, Danchin N, et al. Healthy sleep score changes and incident cardiovascular disease in European prospective community-based cohorts. European Heart Journal. 2023; 44: 4968–4978. https://doi.org/10.1093/eurheartj/ehad657.

[11] Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022; 146: e18–e43. https://doi.org/10.1161/CIR.0000000000001078.

[12] Nikbakhtian S, Reed AB, Obika BD, Morelli D, Cunningham AC, Aral M, et al. Accelerometer-derived sleep onset timing and cardiovascular disease incidence: a UK Biobank cohort study. European Heart Journal. Digital Health. 2021; 2: 658–666. https://doi.org/10.1093/ehjdh/ztab088.

[13] Jean-Louis G, Williams NJ, Sarpong D, Pandey A, Youngstedt S, Zizi F, et al. Associations between inadequate sleep and obesity in the US adult population: analysis of the national health interview survey (1977–2009). BMC Public Health. 2014; 14: 290. https://doi.org/10.1186/1471-2458-14-290.

[14] Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of Healthy Sleep Duration among Adults–United States, 2014. MMWR. Morbidity and Mortality Weekly Report. 2016; 65: 137–141. https://doi.org/10.15585/mmwr.mm6506a1.

[15] Ravichandran R, Gupta L, Singh M, Nag A, Thomas J, Panjiyar BK. The Interplay Between Sleep Disorders and Cardiovascular Diseases: A Systematic Review. Cureus. 2023; 15: e45898. https://doi.org/10.7759/cureus.45898.

[16] Hoevenaar-Blom MP, Spijkerman AMW, Kromhout D, van den Berg JF, Verschuren WMM. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN study. Sleep. 2011; 34: 1487–1492. https://doi.org/10.5665/sleep.1382.

[17] Ai S, Zhang J, Zhao G, Wang N, Li G, So HC, et al. Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank. European Heart Journal. 2021; 42: 3349–3357. https://doi.org/10.1093/eurheartj/ehab170.

[18] Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, et al. A prospective study of sleep duration and coronary heart disease in women. Archives of Internal Medicine. 2003; 163: 205–209. https://doi.org/10.1001/archinte.163.2.205.

[19] Chandola T, Ferrie JE, Perski A, Akbaraly T, Marmot MG. The effect of short sleep duration on coronary heart disease risk is greatest among those with sleep disturbance: a prospective study from the Whitehall II cohort. Sleep. 2010; 33: 739–744. https://doi.org/10.1093/sleep/33.6.739.

[20] Sadabadi F, Darroudi S, Esmaily H, Asadi Z, Ferns GA, Mohammadpour AH, et al. The importance of sleep patterns in the incidence of coronary heart disease: a 6-year prospective study in Mashhad, Iran. Scientific Reports. 2023; 13: 2903. https://doi.org/10.1038/s41598-023-29451-w.

[21] Barger LK, Rajaratnam SMW, Cannon CP, Lukas MA, Im K, Goodrich EL, et al. Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. Journal of the American Heart Association. 2017; 6: e006959. https://doi.org/10.1161/JAHA.117.006959.

[22] Zhu H, Qin S, Wu M. Association between weekend catch-up sleep and cardiovascular disease: Evidence from the National Health and Nutrition Examination Surveys 2017-2018. Sleep Health. 2024; 10: 98–103. https://doi.org/10.1016/j.sleh.2023.09.006.

[23] Wang Z, Yang W, Li X, Qi X, Pan KY, Xu W. Association of Sleep Duration, Napping, and Sleep Patterns With Risk of Cardiovascular Diseases: A Nationwide Twin Study. Journal of the American Heart Association. 2022; 11: e025969. https://doi.org/10.1161/JAHA.122.025969.

[24] Strand LB, Tsai MK, Gunnell D, Janszky I, Wen CP, Chang SS. Self-reported sleep duration and coronary heart disease mortality: A large cohort study of 400,000 Taiwanese adults. International Journal of Cardiology. 2016; 207: 246–251. https://doi.org/10.1016/j.ijcard.2016.01.044.

[25] Svensson T, Saito E, Svensson AK, Melander O, Orho-Melander M, Mimura M, et al. Association of Sleep Duration With All- and Major-Cause Mortality Among Adults in Japan, China, Singapore, and Korea. JAMA Network Open. 2021; 4: e2122837. https://doi.org/10.1001/jamanetworkopen.2021.22837.

[26] Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. European Heart Journal. 2011; 32: 1484–1492. https://doi.org/10.1093/eurheartj/ehr007.

[27] Yin J, Jin X, Shan Z, Li S, Huang H, Li P, et al. Relationship of Sleep Duration With All-Cause Mortality and Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Journal of the American Heart Association. 2017; 6: e005947. https://doi.org/10.1161/JAHA.117.005947.

[28] Li C, Luo SX, Liang TW, Song D, Fu JX. Gender correlation between sleep duration and risk of coronary heart disease: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2025; 12: 1452006. https://doi.org/10.3389/fcvm.2025.1452006.

[29] Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989; 28: 193–213. https://doi.org/10.1016/0165-1781(89)90047-4.

[30] Nelson KL, Davis JE, Corbett CF. Sleep quality: An evolutionary concept analysis. Nursing Forum. 2022; 57: 144–151. https://doi.org/10.1111/nuf.12659.

[31] Westerlund A, Bellocco R, Sundström J, Adami HO, Åkerstedt T, Trolle Lagerros Y. Sleep characteristics and cardiovascular events in a large Swedish cohort. European Journal of Epidemiology. 2013; 28: 463–473. https://doi.org/10.1007/s10654-013-9802-2.

[32] Twig G, Shina A, Afek A, Derazne E, Tzur D, Cukierman-Yaffe T, et al. Sleep quality and risk of diabetes and coronary artery disease among young men. Acta Diabetologica. 2016; 53: 261–270. https://doi.org/10.1007/s00592-015-0779-z.

[33] Zhang B, Wang Y, Liu X, Zhai Z, Sun J, Yang J, et al. The association of sleep quality and night sleep duration with coronary heart disease in a large-scale rural population. Sleep Medicine. 2021; 87: 233–240. https://doi.org/10.1016/j.sleep.2021.09.013.

[34] Song C, Zhang R, Liao J, Fu R, Wang C, Liu Q, et al. Sleep quality and risk of coronary heart disease - a prospective cohort study from the English longitudinal study of ageing. Aging. 2020; 12: 25005–25019. https://doi.org/10.18632/aging.103866.

[35] Andrechuk CRS, Ceolim MF. Sleep quality and adverse outcomes for patients with acute myocardial infarction. Journal of Clinical Nursing. 2016; 25: 223–230. https://doi.org/10.1111/jocn.13051.

[36] Yang J, Wang K, Wang W, Niu J, Liu X, Shen H, et al. The Effect of Sleep Quality on Coronary Lesion Severity and Prognosis in the Young Acute Coronary Syndrome Population. Journal of Cardiovascular Development and Disease. 2024; 11: 68. https://doi.org/10.3390/jcdd11020068.

[37] Hu J, Wang X, Cheng L, Dang K, Ming Z, Tao X, et al. Sleep patterns and risks of incident cardiovascular disease and mortality among people with type 2 diabetes: a prospective study of the UK Biobank. Diabetology & Metabolic Syndrome. 2024; 16: 15. https://doi.org/10.1186/s13098-024-01261-8.

[38] Bin YS. Is Sleep Quality More Important Than Sleep Duration for Public Health? Sleep. 2016; 39: 1629–1630. https://doi.org/10.5665/sleep.6078.

[39] Yang TC, Park K. To What Extent do Sleep Quality and Duration Mediate the Effect of Perceived Discrimination on Health? Evidence from Philadelphia. Journal of Urban Health: Bulletin of the New York Academy of Medicine. 2015; 92: 1024–1037. https://doi.org/10.1007/s11524-015-9986-8.

[40] Holder S, Narula NS. Common Sleep Disorders in Adults: Diagnosis and Management. American Family Physician. 2022; 105: 397–405.

[41] Edinger JD, Bonnet MH, Bootzin RR, Doghramji K, Dorsey CM, Espie CA, et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep. 2004; 27: 1567–1596. https://doi.org/10.1093/sleep/27.8.1567.

[42] Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep Medicine. 2015; 16: 372–378. https://doi.org/10.1016/j.sleep.2014.12.008.

[43] Roth T, Coulouvrat C, Hajak G, Lakoma MD, Sampson NA, Shahly V, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biological Psychiatry. 2011; 69: 592–600. https://doi.org/10.1016/j.biopsych.2010.10.023.

[44] Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: Analysis of the 2002 national health interview survey data. Archives of Internal Medicine. 2006; 166: 1775–1782. https://doi.org/10.1001/archinte.166.16.1775.

[45] Riemann D, Espie CA, Altena E, Arnardottir ES, Baglioni C, Bassetti CLA, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research. 2023; 32: e14035. https://doi.org/10.1111/jsr.14035.

[46] Leineweber C, Kecklund G, Janszky I, Akerstedt T, Orth-Gomér K. Poor sleep increases the prospective risk for recurrent events in middle-aged women with coronary disease. The Stockholm Female Coronary Risk Study. Journal of Psychosomatic Research. 2003; 54: 121–127. https://doi.org/10.1016/s0022-3999(02)00475-0.

[47] Meisinger C, Heier M, Löwel H, Schneider A, Döring A. Sleep duration and sleep complaints and risk of myocardial infarction in middle-aged men and women from the general population: the MONICA/KORA Augsburg cohort study. Sleep. 2007; 30: 1121–1127. https://doi.org/10.1093/sleep/30.9.1121.

[48] Coryell VT, Ziegelstein RC, Hirt K, Quain A, Marine JE, Smith MT. Clinical correlates of insomnia in patients with acute coronary syndrome. International Heart Journal. 2013; 54: 258–265. https://doi.org/10.1536/ihj.54.258.

[49] Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011; 124: 2073–2081. https://doi.org/10.1161/CIRCULATIONAHA.111.025858.

[50] Hsu CY, Chen YT, Chen MH, Huang CC, Chiang CH, Huang PH, et al. The Association Between Insomnia and Increased Future Cardiovascular Events: A Nationwide Population-Based Study. Psychosomatic Medicine. 2015; 77: 743–751. https://doi.org/10.1097/PSY.0000000000000199.

[51] Frøjd LA, Dammen T, Munkhaugen J, Weedon-Fekjær H, Nordhus IH, Papageorgiou C, et al. Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease. Sleep Advances: a Journal of the Sleep Research Society. 2022; 3: zpac007. https://doi.org/10.1093/sleepadvances/zpac007.

[52] Dean YE, Shebl MA, Rouzan SS, Bamousa BAA, Talat NE, Ansari SA, et al. Association between insomnia and the incidence of myocardial infarction: A systematic review and meta-analysis. Clinical Cardiology. 2023; 46: 376–385. https://doi.org/10.1002/clc.23984.

[53] Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. European Journal of Preventive Cardiology. 2014; 21: 57–64. https://doi.org/10.1177/2047487312460020.

[54] Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. International Journal of Cardiology. 2014; 176: 1044–1047. https://doi.org/10.1016/j.ijcard.2014.07.284.

[55] Powell TA, Mysliwiec V, Brock MS, Morris MJ. OSA and cardiorespiratory fitness: a review. Journal of Clinical Sleep Medicine. 2022; 18: 279–288. https://doi.org/10.5664/jcsm.9628.

[56] Toraldo DM, Piscitelli P, De Nuccio F. Obstructive Sleep Apnoea (OSA) and early atherosclerosis: The role of microbiota and EVs. Pulmonology. 2024; 30: 506–508. https://doi.org/10.1016/j.pulmoe.2023.11.011.

[57] de Araujo Dantas AB, Gonçalves FM, Martins AA, Alves GÂ Stechman-Neto J, Corrêa CDC, et al. Worldwide prevalence and associated risk factors of obstructive sleep apnea: a meta-analysis and meta-regression. Sleep Breath. 2023; 27: 2083–2109. https://doi.org/10.1007/s11325-023-02810-7.

[58] Tan JWC, Leow LC, Wong S, Khoo SM, Kasai T, Kojodjojo P, et al. Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Obstructive Sleep Apnoea in Patients with Cardiovascular Disease. European Cardiology. 2022; 17: e16. https://doi.org/10.15420/ecr.2021.59.

[59] Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alcántara C, et al. Racial/Ethnic Differences in Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA). Sleep. 2015; 38: 877–888. https://doi.org/10.5665/sleep.4732.

[60] Tan A, Hau W, Ho HH, Ghaem Maralani H, Loo G, Khoo SM, et al. OSA and coronary plaque characteristics. Chest. 2014; 145: 322–330. https://doi.org/10.1378/chest.13-1163.

[61] Mooe T, Franklin KA, Wiklund U, Rabben T, Holmström K. Sleep-disordered breathing and myocardial ischemia in patients with coronary artery disease. Chest. 2000; 117: 1597–1602. https://doi.org/10.1378/chest.117.6.1597.

[62] Hao W, Wang B, Fan J, Que B, Ai H, Wang X, et al. Obstructive sleep apnea is associated with the long-term prognosis of patients in acute coronary syndromes with prior myocardial infarction: Insights from OSA-ACS study. Sleep Medicine. 2023; 112: 141–148. https://doi.org/10.1016/j.sleep.2023.10.009.

[63] Lee CH, Khoo SM, Chan MY, Wong HB, Low AF, Phua QH, et al. Severe obstructive sleep apnea and outcomes following myocardial infarction. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine. 2011; 7: 616–621. https://doi.org/10.5664/jcsm.1464.

[64] Hao W, Wang X, Fan J, Zeng Y, Ai H, Nie S, et al. Association between apnea-hypopnea index and coronary artery calcification: a systematic review and meta-analysis. Annals of Medicine. 2021; 53: 302–317. https://doi.org/10.1080/07853890.2021.1875137.

[65] Konishi T, Kashiwagi Y, Funayama N, Yamamoto T, Murakami H, Hotta D, et al. Obstructive sleep apnea is associated with increased coronary plaque instability: an optical frequency domain imaging study. Heart and Vessels. 2019; 34: 1266–1279. https://doi.org/10.1007/s00380-019-01363-8.

[66] Nakashima H, Kurobe M, Minami K, Furudono S, Uchida Y, Amenomori K, et al. Effects of moderate-to-severe obstructive sleep apnea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome. European Heart Journal. Acute Cardiovascular Care. 2015; 4: 75–84. https://doi.org/10.1177/2048872614530865.

[67] Behnoush AH, Khalaji A, Ghondaghsaz E, Masrour M, Shokri Varniab Z, Khalaji S, et al. Triglyceride-glucose index and obstructive sleep apnea: a systematic review and meta-analysis. Lipids in Health and Disease. 2024; 23: 4. https://doi.org/10.1186/s12944-024-02005-3.

[68] Behnoush AH, Bahiraie P, Shokri Varniab Z, Foroutani L, Khalaji A. Composite lipid indices in patients with obstructive sleep apnea: a systematic review and meta-analysis. Lipids in Health and Disease. 2023; 22: 84. https://doi.org/10.1186/s12944-023-01859-3.

[69] Thareja S, Mandapalli R, Shaik F, Rajeev Pillai A, Palaniswamy G, Sahu S, et al. Impact of Obstructive Sleep Apnea on Cardiovascular Health: A Systematic Review. Cureus. 2024; 16: e71940. https://doi.org/10.7759/cureus.71940.

[70] Lui MMS, Tse HF, Lam DCL, Lau KK, Chan CWS, Ip MSM. Continuous positive airway pressure improves blood pressure and serum cardiovascular biomarkers in obstructive sleep apnoea and hypertension. The European Respiratory Journal. 2021; 58: 2003687. https://doi.org/10.1183/13993003.03687-2020.

[71] Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet (London, England). 2005; 365: 1046–1053. https://doi.org/10.1016/S0140-6736(05)71141-7.

[72] Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 2016; 194: 613–620. https://doi.org/10.1164/rccm.201601-0088OC.

[73] Wang X, Zhang Y, Dong Z, Fan J, Nie S, Wei Y. Effect of continuous positive airway pressure on long-term cardiovascular outcomes in patients with coronary artery disease and obstructive sleep apnea: a systematic review and meta-analysis. Respiratory Research. 2018; 19: 61. https://doi.org/10.1186/s12931-018-0761-8.

[74] Li H, Pan Y, Lou Y, Zhang Y, Yin L, Sanderson JE, et al. The Effects of Continuous Positive Airway Pressure Therapy for Secondary Cardiovascular Prevention in Patients with Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis. Reviews in Cardiovascular Medicine. 2022; 23: 195. https://doi.org/10.31083/j.rcm2306195.

[75] Yatsu S, Kasai T, Suda S, Matsumoto H, Ishiwata S, Shiroshita N, et al. Prevalence and Significance of Restless Legs Syndrome in Patients With Coronary Artery Disease. The American Journal of Cardiology. 2019; 123: 1580–1586. https://doi.org/10.1016/j.amjcard.2019.02.017.

[76] Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Medicine Reviews. 2012; 16: 283–295. https://doi.org/10.1016/j.smrv.2011.05.002.

[77] De Vito K, Li Y, Batool-Anwar S, Ning Y, Han J, Gao X. Prospective study of obesity, hypertension, high cholesterol, and risk of restless legs syndrome. Movement Disorders: Official Journal of the Movement Disorder Society. 2014; 29: 1044–1052. https://doi.org/10.1002/mds.25860.

[78] Schlesinger I, Erikh I, Avizohar O, Sprecher E, Yarnitsky D. Cardiovascular risk factors in restless legs syndrome. Movement Disorders: Official Journal of the Movement Disorder Society. 2009; 24: 1587–1592. https://doi.org/10.1002/mds.22486.

[79] Aksoy D, Çelik A, Solmaz V, Çevik B, Sümbül O, Kurt S. The prevalence of restless legs syndrome in patients undergoing coronary angiography and its relationship with the severity of coronary artery stenosis. Sleep Breath. 2021; 25: 257–262. https://doi.org/10.1007/s11325-020-02085-2.

[80] Almuwaqqat Z, Kim JH, Islam SJ, Mehta A, Ahmad S, Wehbe M, et al. Usefulness of Restless Legs Symptoms to Predict Adverse Cardiovascular Outcomes in Men With Coronary Artery Disease. The American Journal of Cardiology. 2022; 162: 41–48. https://doi.org/10.1016/j.amjcard.2021.08.054.

[81] Van Den Eeden SK, Albers KB, Davidson JE, Kushida CA, Leimpeter AD, Nelson LM, et al. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California. Sleep. 2015; 38: 1009–1015. https://doi.org/10.5665/sleep.4800.

[82] Antonopoulos AS, Angelopoulos A, Papanikolaou P, Simantiris S, Oikonomou EK, Vamvakaris K, et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. JACC. Cardiovascular Imaging. 2022; 15: 460–471. https://doi.org/10.1016/j.jcmg.2021.09.014.

[83] Gao M, Tang M, Ho W, Teng Y, Chen Q, Bu L, et al. Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis. ACS Nano. 2023; 17: 17721–17739. https://doi.org/10.1021/acsnano.3c00958.

[84] Goswami SK, Ranjan P, Dutta RK, Verma SK. Management of inflammation in cardiovascular diseases. Pharmacological Research. 2021; 173: 105912. https://doi.org/10.1016/j.phrs.2021.105912.

[85] Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biological Psychiatry. 2016; 80: 40–52. https://doi.org/10.1016/j.biopsych.2015.05.014.

[86] Sang D, Lin K, Yang Y, Ran G, Li B, Chen C, et al. Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. Cell. 2023; 186: 5500–5516.e21. https://doi.org/10.1016/j.cell.2023.10.025.

[87] Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Archives of Internal Medicine. 2006; 166: 1756–1762. https://doi.org/10.1001/archinte.166.16.1756.

[88] van Leeuwen WMA, Lehto M, Karisola P, Lindholm H, Luukkonen R, Sallinen M, et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PloS One. 2009; 4: e4589. https://doi.org/10.1371/journal.pone.0004589.

[89] Parthasarathy S, Vasquez MM, Halonen M, Bootzin R, Quan SF, Martinez FD, et al. Persistent insomnia is associated with mortality risk. The American Journal of Medicine. 2015; 128: 268–275.e2. https://doi.org/10.1016/j.amjmed.2014.10.015.

[90] Mehra R, Storfer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, et al. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Archives of Internal Medicine. 2006; 166: 1725–1731. https://doi.org/10.1001/archinte.166.16.1725.

[91] Xie X, Pan L, Ren D, Du C, Guo Y. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis. Sleep Medicine. 2013; 14: 1139–1150. https://doi.org/10.1016/j.sleep.2013.07.006.

[92] Paz Y Mar HL, Hazen SL, Tracy RP, Strohl KP, Auckley D, Bena J, et al. Effect of Continuous Positive Airway Pressure on Cardiovascular Biomarkers: The Sleep Apnea Stress Randomized Controlled Trial. Chest. 2016; 150: 80–90. https://doi.org/10.1016/j.chest.2016.03.002.

[93] Wen Y, Zhang H, Tang Y, Yan R. Research on the Association Between Obstructive Sleep Apnea Hypopnea Syndrome Complicated With Coronary Heart Disease and Inflammatory Factors, Glycolipid Metabolism, Obesity, and Insulin Resistance. Frontiers in Endocrinology. 2022; 13: 854142. https://doi.org/10.3389/fendo.2022.854142.

[94] Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Current Atherosclerosis Reports. 2017; 19: 42. https://doi.org/10.1007/s11883-017-0678-6.

[95] Mury P, Chirico EN, Mura M, Millon A, Canet-Soulas E, Pialoux V. Oxidative Stress and Inflammation, Key Targets of Atherosclerotic Plaque Progression and Vulnerability: Potential Impact of Physical Activity. Sports Medicine (Auckland, N.Z.). 2018; 48: 2725–2741. https://doi.org/10.1007/s40279-018-0996-z.

[96] Atrooz F, Salim S. Sleep deprivation, oxidative stress and inflammation. Advances in Protein Chemistry and Structural Biology. 2020; 119: 309–336. https://doi.org/10.1016/bs.apcsb.2019.03.001.

[97] Vaccaro A, Kaplan Dor Y, Nambara K, Pollina EA, Lin C, Greenberg ME, et al. Sleep Loss Can Cause Death through Accumulation of Reactive Oxygen Species in the Gut. Cell. 2020; 181: 1307–1328.e15. https://doi.org/10.1016/j.cell.2020.04.049.

[98] Shah R, Shah VK, Emin M, Gao S, Sampogna RV, Aggarwal B, et al. Mild sleep restriction increases endothelial oxidative stress in female persons. Scientific Reports. 2023; 13: 15360. https://doi.org/10.1038/s41598-023-42758-y.

[99] Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. The Journal of Clinical Investigation. 1999; 103: 1547–1560. https://doi.org/10.1172/JCI5549.

[100] Boudjeltia KZ, Faraut B, Esposito MJ, Stenuit P, Dyzma M, Antwerpen PV, et al. Temporal dissociation between myeloperoxidase (MPO)-modified LDL and MPO elevations during chronic sleep restriction and recovery in healthy young men. PloS One. 2011; 6: e28230. https://doi.org/10.1371/journal.pone.0028230.

[101] Orrù G, Storari M, Scano A, Piras V, Taibi R, Viscuso D. Obstructive Sleep Apnea, oxidative stress, inflammation and endothelial dysfunction-An overview of predictive laboratory biomarkers. European Review for Medical and Pharmacological Sciences. 2020; 24: 6939–6948. https://doi.org/10.26355/eurrev_202006_21685.

[102] Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Current Vascular Pharmacology. 2014; 12: 4–15. https://doi.org/10.2174/15701611113119990140.

[103] Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiological Reviews. 2010; 90: 513–557. https://doi.org/10.1152/physrev.00007.2009.

[104] Greenlund IM, Carter JR. Sympathetic neural responses to sleep disorders and insufficiencies. American Journal of Physiology. Heart and Circulatory Physiology. 2022; 322: H337–H349. https://doi.org/10.1152/ajpheart.00590.2021.

[105] Tobaldini E, Cogliati C, Fiorelli EM, Nunziata V, Wu MA, Prado M, et al. One night on-call: sleep deprivation affects cardiac autonomic control and inflammation in physicians. European Journal of Internal Medicine. 2013; 24: 664–670. https://doi.org/10.1016/j.ejim.2013.03.011.

[106] Sauvet F, Leftheriotis G, Gomez-Merino D, Langrume C, Drogou C, Van Beers P, et al. Effect of acute sleep deprivation on vascular function in healthy subjects. Journal of Applied Physiology (Bethesda, Md.: 1985). 2010; 108: 68–75. https://doi.org/10.1152/japplphysiol.00851.2009.

[107] Zhang J, Ma RCW, Kong APS, So WY, Li AM, Lam SP, et al. Relationship of sleep quantity and quality with 24-hour urinary catecholamines and salivary awakening cortisol in healthy middle-aged adults. Sleep. 2011; 34: 225–233. https://doi.org/10.1093/sleep/34.2.225.

[108] Covassin N, Bukartyk J, Singh P, Calvin AD, St Louis EK, Somers VK. Effects of Experimental Sleep Restriction on Ambulatory and Sleep Blood Pressure in Healthy Young Adults: A Randomized Crossover Study. Hypertension (Dallas, Tex.: 1979). 2021; 78: 859–870. https://doi.org/10.1161/HYPERTENSIONAHA.121.17622.

[109] Grimaldi D, Carter JR, Van Cauter E, Leproult R. Adverse Impact of Sleep Restriction and Circadian Misalignment on Autonomic Function in Healthy Young Adults. Hypertension (Dallas, Tex.: 1979). 2016; 68: 243–250. https://doi.org/10.1161/HYPERTENSIONAHA.115.06847.

[110] Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension (Dallas, Tex.: 1979). 2006; 47: 833–839. https://doi.org/10.1161/01.HYP.0000217362.34748.e0.

[111] Gottlieb DJ, Redline S, Nieto FJ, Baldwin CM, Newman AB, Resnick HE, et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep. 2006; 29: 1009–1014. https://doi.org/10.1093/sleep/29.8.1009.

[112] Carlson JT, Hedner JA, Sellgren J, Elam M, Wallin BG. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine. 1996; 154: 1490–1496. https://doi.org/10.1164/ajrccm.154.5.8912770.

[113] Narkiewicz K, van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation. 1998; 97: 943–945. https://doi.org/10.1161/01.cir.97.10.943.

[114] Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation. 1999; 99: 1183–1189. https://doi.org/10.1161/01.cir.99.9.1183.

[115] Narkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, Somers VK. Altered cardiovascular variability in obstructive sleep apnea. Circulation. 1998; 98: 1071–1077. https://doi.org/10.1161/01.cir.98.11.1071.

[116] Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. Journal of the American College of Cardiology. 2017; 69: 1952–1967. https://doi.org/10.1016/j.jacc.2017.01.064.

[117] Wang Y, Carreras A, Lee S, Hakim F, Zhang SX, Nair D, et al. Chronic sleep fragmentation promotes obesity in young adult mice. Obesity (Silver Spring, Md.). 2014; 22: 758–762. https://doi.org/10.1002/oby.20616.

[118] Tracey KJ. The inflammatory reflex. Nature. 2002; 420: 853–859. https://doi.org/10.1038/nature01321.

[119] Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Translational Research: the Journal of Laboratory and Clinical Medicine. 2017; 183: 57–70. https://doi.org/10.1016/j.trsl.2017.01.001.

[120] Mosavat M, Mirsanjari M, Arabiat D, Smyth A, Whitehead L. The Role of Sleep Curtailment on Leptin Levels in Obesity and Diabetes Mellitus. Obesity Facts. 2021; 14: 214–221. https://doi.org/10.1159/000514095.

[121] Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine. 2004; 141: 846–850. https://doi.org/10.7326/0003-4819-141-11-200412070-00008.

[122] Parrish JB, Teske JA. Acute partial sleep deprivation due to environmental noise increases weight gain by reducing energy expenditure in rodents. Obesity (Silver Spring, Md.). 2017; 25: 141–146. https://doi.org/10.1002/oby.21703.

[123] Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care. 2009; 32: 1980–1985. https://doi.org/10.2337/dc09-0284.

[124] Knutson KL, Van Cauter E, Zee P, Liu K, Lauderdale DS. Cross-sectional associations between measures of sleep and markers of glucose metabolism among subjects with and without diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Sleep Study. Diabetes Care. 2011; 34: 1171–1176. https://doi.org/10.2337/dc10-1962.

[125] Wang B, Zhang H, Sun Y, Tan X, Zhang J, Wang N, et al. Association of sleep patterns and cardiovascular disease risk is modified by glucose tolerance status. Diabetes/metabolism Research and Reviews. 2023; 39: e3642. https://doi.org/10.1002/dmrr.3642.

[126] Liang YY, Chen J, Peng M, Zhou J, Chen X, Tan X, et al. Association between sleep duration and metabolic syndrome: linear and nonlinear Mendelian randomization analyses. Journal of Translational Medicine. 2023; 21: 90. https://doi.org/10.1186/s12967-023-03920-2.

[127] Liu X, Li C, Sun X, Yu Y, Si S, Hou L, et al. Genetically Predicted Insomnia in Relation to 14 Cardiovascular Conditions and 17 Cardiometabolic Risk Factors: A Mendelian Randomization Study. Journal of the American Heart Association. 2021; 10: e020187. https://doi.org/10.1161/JAHA.120.020187.

[128] Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. The Journal of Clinical Endocrinology and Metabolism. 2001; 86: 3787–3794. https://doi.org/10.1210/jcem.86.8.7778.

[129] Rodenbeck A, Cohrs S, Jordan W, Huether G, Rüther E, Hajak G. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology. 2003; 170: 423–428. https://doi.org/10.1007/s00213-003-1565-0.

[130] Vgontzas AN, Tsigos C, Bixler EO, Stratakis CA, Zachman K, Kales A, et al. Chronic insomnia and activity of the stress system: a preliminary study. Journal of Psychosomatic Research. 1998; 45: 21–31. https://doi.org/10.1016/s0022-3999(97)00302-4.

[131] Floam S, Simpson N, Nemeth E, Scott-Sutherland J, Gautam S, Haack M. Sleep characteristics as predictor variables of stress systems markers in insomnia disorder. Journal of Sleep Research. 2015; 24: 296–304. https://doi.org/10.1111/jsr.12259.

[132] Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. The New England Journal of Medicine. 1984; 310: 1137–1140. https://doi.org/10.1056/NEJM198405033101801.

[133] Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. British Heart Journal. 1983; 50: 127–134. https://doi.org/10.1136/hrt.50.2.127.

[134] Davì G, Patrono C. Platelet activation and atherothrombosis. The New England Journal of Medicine. 2007; 357: 2482–2494. https://doi.org/10.1056/NEJMra071014.

[135] Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. The New England Journal of Medicine. 1986; 315: 983–989. https://doi.org/10.1056/NEJM198610163151602.

[136] Wang C, Li L, Yang C, Zhang Z, Li X, Wang Y, et al. One night of sleep deprivation induces release of small extracellular vesicles into circulation and promotes platelet activation by small EVs. Journal of Cellular and Molecular Medicine. 2022; 26: 5033–5043. https://doi.org/10.1111/jcmm.17528.

[137] Bikov A, Meszaros M, Schwarz EI. Coagulation and Fibrinolysis in Obstructive Sleep Apnoea. International Journal of Molecular Sciences. 2021; 22: 2834. https://doi.org/10.3390/ijms22062834.

[138] Krieger AC, Anand R, Hernandez-Rosa E, Maidman A, Milrad S, DeGrazia MQ, et al. Increased platelet activation in sleep apnea subjects with intermittent hypoxemia. Sleep Breath. 2020; 24: 1537–1547. https://doi.org/10.1007/s11325-020-02021-4.

[139] von Känel R, Loredo JS, Ancoli-Israel S, Mills PJ, Natarajan L, Dimsdale JE. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest. 2007; 131: 733–739. https://doi.org/10.1378/chest.06-2006.

[140] Miller MA, Kandala NB, Kumari M, Marmot MG, Cappuccio FP. Relationships between sleep duration and von Willebrand factor, factor VII, and fibrinogen: Whitehall II study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010; 30: 2032–2038. https://doi.org/10.1161/ATVBAHA.110.206987.

Funding

National Key Research and Development Program of China(2022YFC3602400)

National Key Research and Development Program of China(2022YFC3602404)

National Natural Science Foundation of China(82270474)

Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases)(2023-FZX18)